INDV Indivior Pharmaceuticals, Inc.

NASDAQ

$35.82

Indivior Pharmaceuticals, Inc. (INDV) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is $0.93 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.1% since its last earnings release on August 3, 2026.

Indivior Pharmaceuticals Beat Consensus Estimates, Raises Guidance

Monday, August 3, 2026 · 6:31 AM ET

3rd Quarter, Sep 2026

Monday · 6:30 AM ET

Earnings Whisper

-

vs $0.93

Rev est $326.7M

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $36.50

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Indivior Pharmaceuticals, Inc.

Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.